These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 25281617)

  • 21. A study of the suppressive effect on human pancreatic adenocarcinoma cell proliferation and angiogenesis by stable plasmid-based siRNA silencing of c-Src gene expression.
    Zhao X; Li DC; Zhao H; Li Z; Wang JX; Zhu DM; Zhou J; Cen JN
    Oncol Rep; 2012 Mar; 27(3):628-36. PubMed ID: 22200682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics.
    Gentile E; Oba T; Lin J; Shao R; Meng F; Cao X; Lin HY; Mourad M; Pataer A; Baladandayuthapani V; Cai D; Roth JA; Ji L
    Oncotarget; 2017 Jul; 8(29):48222-48239. PubMed ID: 28637023
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
    Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
    Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts.
    Grzelinski M; Urban-Klein B; Martens T; Lamszus K; Bakowsky U; Höbel S; Czubayko F; Aigner A
    Hum Gene Ther; 2006 Jul; 17(7):751-66. PubMed ID: 16839274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Centyrin ligands for extrahepatic delivery of siRNA.
    Klein D; Goldberg S; Theile CS; Dambra R; Haskell K; Kuhar E; Lin T; Parmar R; Manoharan M; Richter M; Wu M; Mendrola Zarazowski J; Jadhav V; Maier MA; Sepp-Lorenzino L; O'Neil K; Dudkin V
    Mol Ther; 2021 Jun; 29(6):2053-2066. PubMed ID: 33601052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab.
    Höbel S; Koburger I; John M; Czubayko F; Hadwiger P; Vornlocher HP; Aigner A
    J Gene Med; 2010 Mar; 12(3):287-300. PubMed ID: 20052738
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD44 targeted delivery of siRNA by using HA-decorated nanotechnologies for KRAS silencing in cancer treatment.
    Tirella A; Kloc-Muniak K; Good L; Ridden J; Ashford M; Puri S; Tirelli N
    Int J Pharm; 2019 Apr; 561():114-123. PubMed ID: 30822503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS.
    Zhang XH; Cheng Y; Shin JY; Kim JO; Oh JE; Kang JH
    Cancer Biol Ther; 2013 Jul; 14(7):597-605. PubMed ID: 23792647
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual Functional LipoMET Mediates Envelope-type Nanoparticles to Combinational Oncogene Silencing and Tumor Growth Inhibition.
    Shi K; Zhao Y; Miao L; Satterlee A; Haynes M; Luo C; Musetti S; Huang L
    Mol Ther; 2017 Jul; 25(7):1567-1579. PubMed ID: 28274796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.
    Sunaga N; Shames DS; Girard L; Peyton M; Larsen JE; Imai H; Soh J; Sato M; Yanagitani N; Kaira K; Xie Y; Gazdar AF; Mori M; Minna JD
    Mol Cancer Ther; 2011 Feb; 10(2):336-46. PubMed ID: 21306997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A self-assembled polyjuglanin nanoparticle loaded with doxorubicin and anti-Kras siRNA for attenuating multidrug resistance in human lung cancer.
    Wen ZM; Jie J; Zhang Y; Liu H; Peng LP
    Biochem Biophys Res Commun; 2017 Dec; 493(4):1430-1437. PubMed ID: 28958938
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor-targeted Nanoparticle Delivery of HuR siRNA Inhibits Lung Tumor Growth
    Muralidharan R; Babu A; Amreddy N; Srivastava A; Chen A; Zhao YD; Kompella UB; Munshi A; Ramesh R
    Mol Cancer Ther; 2017 Aug; 16(8):1470-1486. PubMed ID: 28572169
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Knockdown of ribosomal protein L39 by RNA interference inhibits the growth of human pancreatic cancer cells in vitro and in vivo.
    Li C; Chen D; Luo M; Ge M; Zhu J
    Biotechnol J; 2014 May; 9(5):652-63. PubMed ID: 24799381
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo activation of PEGylated long circulating lipid nanoparticle to achieve efficient siRNA delivery and target gene knock down in solid tumors.
    Sasayama Y; Hasegawa M; Taguchi E; Kubota K; Kuboyama T; Naoi T; Yabuuchi H; Shimai N; Asano M; Tokunaga A; Ishii T; Enokizono J
    J Control Release; 2019 Oct; 311-312():245-256. PubMed ID: 31505222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy.
    Yang XZ; Dou S; Sun TM; Mao CQ; Wang HX; Wang J
    J Control Release; 2011 Dec; 156(2):203-11. PubMed ID: 21839126
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy.
    Santel A; Aleku M; Keil O; Endruschat J; Esche V; Durieux B; Löffler K; Fechtner M; Röhl T; Fisch G; Dames S; Arnold W; Giese K; Klippel A; Kaufmann J
    Gene Ther; 2006 Sep; 13(18):1360-70. PubMed ID: 16625242
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumors.
    Anthiya S; Öztürk SC; Yanik H; Tavukcuoglu E; Şahin A; Datta D; Charisse K; Álvarez DM; Loza MI; Calvo A; Sulheim E; Loevenich S; Klinkenberg G; Schmid R; Manoharan M; Esendağlı G; Alonso MJ
    J Control Release; 2023 May; 357():67-83. PubMed ID: 36921725
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transcriptional gene silencing of HPV16 E6/E7 induces growth inhibition via apoptosis in vitro and in vivo.
    Zhou J; Peng C; Li B; Wang F; Zhou C; Hong D; Ye F; Cheng X; Lü W; Xie X
    Gynecol Oncol; 2012 Feb; 124(2):296-302. PubMed ID: 22056554
    [TBL] [Abstract][Full Text] [Related]  

  • 39. siRNA Lipid Nanoparticle Potently Silences Clusterin and Delays Progression When Combined with Androgen Receptor Cotargeting in Enzalutamide-Resistant Prostate Cancer.
    Yamamoto Y; Lin PJ; Beraldi E; Zhang F; Kawai Y; Leong J; Katsumi H; Fazli L; Fraser R; Cullis PR; Gleave M
    Clin Cancer Res; 2015 Nov; 21(21):4845-55. PubMed ID: 26106075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Simultaneous gene silencing of KRAS and anti-apoptotic genes as a multitarget therapy.
    Werner K; Lademann F; Thepkaysone ML; Jahnke B; Aust DE; Kahlert C; Weber G; Weitz J; Grützmann R; Pilarsky C
    Oncotarget; 2016 Jan; 7(4):3984-92. PubMed ID: 26716649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.